Recommendations of the Immunization Practices Advisory Committee
Update: Prevention of Haemophilus influenzae Type b Disease
On June 23, 1987, the Immunization Practices Advisory Committee
(ACIP) reviewed preliminary postmarketing surveillance data
presented
at an April 20, 1987, FDA workshop on Haemophilus influenzae type b
(Hib) polysaccharide vaccines (see article below). These data were
evaluated in light of the current ACIP recommendations for use of
the
vaccine (1) and for prophylaxis with rifampin (2) in the prevention
of
invasive Hib disease.
The ACIP believes that the preliminary data from these ongoing
studies do not indicate a need for changes in the present
recommendations for vaccine use. It should be emphasized that
vaccination is not a substitute for prophylaxis with rifampin in
children exposed to Hib disease.
References
Immunization Practices Advisory Committee. Polysaccharide
vaccine
for prevention of Haemophilus influenzae type b disease. MMWR
1985;34:201-5.
2. Immunization Practices Advisory Committee. ACIP: update:
prevention of Haemophilus influenzae type b disease. MMWR
1986;35:170-4,179-80.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
